** Medical device maker Nevro Corp's shares rise 18.6% to $6.31 premarket
** On Monday, co posted Q3 revenue of $96.9 mln vs analysts' est. of $93.1 mln - data compiled by LSEG
** Co reported Q3 loss per share of 41 cents vs est. for loss of 81 cents per share
** Expects 2024 adj. EBITDA loss of $16 mln to $18 mln, smaller than earlier forecast for loss of $18 mln to $20 mln
** As of last close, stock had fallen ~75% YTD, as NVRO has struggled with weak demand for some of its products and had earlier cut its revenue forecast
** J.P. Morgan says Nevro's management expects outlook to improve in 2025, but brokerage views Nevro as "a 'show me' story" as it tries to reach breakeven
** Twelve of 16 brokerages rate the stock "hold" and 4 "sell" or lower; median PT is $6.50 - LSEG data
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。